成人无关供者造血细胞移植中抗胸腺细胞球蛋白暴露与生存结局的关联:一项多中心回顾性药效学队列分析
这项多中心回顾性药动学-药效学分析纳入146例接受首次T细胞去除的异基因外周血干细胞移植、以兔抗胸腺细胞球蛋白(thymoglobulin)作为非清髓性预处理组成部分的急性白血病或骨髓增生异常综合征成人患者,发现移植后ATG暴露是5年总生存的最佳预测因素,最佳暴露为60-95 AU/天/mL,最佳暴露组5年总生存显著高于低于和高于最佳暴露组。
要点
- 移植后ATG暴露是成人无关供者HCT后5年总生存的最佳预测因素。
- 最佳暴露为60-95 AU/天/mL,最佳组5年总生存69%显著高于低于组32%和高于组48%。
- 基于淋巴细胞计数的个体化给药较按体重给药更能达到最佳暴露目标。
核心结论
- ATG暴露影响成人HCT后生存,强调最佳ATG给药的重要性。
- 基于淋巴细胞计数而非体重的个体化ATG给药可能改善HCT后生存机会。
研究设计与样本
- 多中心、回顾性药动学-药效学队列分析,纳入2004年3月1日至2015年6月1日期间接受首次T细胞去除的异基因外周血干细胞HCT、以兔抗胸腺细胞球蛋白(thymoglobulin)作为非清髓性预处理组成部分的急性淋巴细胞白血病、急性髓系白血病或骨髓增生异常综合征成人患者146例。
- 患者接受累积静脉剂量8 mg/kg分4天给予,从HCT前第-8天开始。
- 采用经验证的生物测定法检测活性ATG浓度,并用经验证的人群药动学模型计算药动学暴露指标。
- 主要结局为5年总生存,其他结局包括复发相关死亡、非复发死亡、无事件生存、急性和慢性GVHD以及当前与最佳给药的评估。
- 采用Cox比例风险模型和Fine-Gray竞争风险模型进行分析。
主要发现
- 最佳暴露组(60-95 AU/天/mL)估计5年总生存为69%(95%CI 55-86),显著高于低于最佳暴露组32%(20-51;p=0.00037;HR 2.41,95%CI 1.15-5.06,p=0.020)和高于最佳暴露组48%(37-62;p=0.030;HR 2.11,95%CI 1.04-4.27,p=0.038)。
- 最佳暴露组无事件生存机会高于低于最佳暴露组(HR 2.54,95%CI 1.29-5.00,p=0.007);高于最佳暴露组HR为1.83(95%CI 0.97-3.47,p=0.063)。
- 高于最佳暴露组复发相关死亡高于最佳暴露组(HR 2.66,95%CI 1.12-6.31;p=0.027)。
- 低于最佳暴露组非复发死亡高于最佳暴露组(HR 4.36,95%CI 1.60-11.88;p=0.0040),3-4级急性GVHD发生率更高(HR 3.09,95%CI 1.12-8.53;p=0.029),但慢性GVHD无显著差异(HR 2.38,95%CI 0.93-6.08;p=0.070)。
- 基于绝对淋巴细胞计数的模型给药较按体重给药达到最佳目标的比例更高。
关键数值与推荐
- 最佳移植后ATG暴露为60-95 AU/天/mL。
- ATG累积静脉剂量8 mg/kg分4天给予,从HCT前第-8天开始。
临床怎么用
- 作者认为ATG暴露影响成人HCT后生存,强调最佳ATG给药的重要性。
- 作者认为基于淋巴细胞计数而非体重的个体化ATG给药可能改善HCT后生存机会。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-thymocyte globulin (ATG) is used to prevent graft-versus-host disease (GvHD) after allogeneic haemopoietic cell transplantation (HCT). However, ATG can also cause delayed immune reconstitution of T cells, negatively affecting survival. We studied the relation between exposure to ATG and clinical outcomes in adult patients with acute leukaemia and myelodysplastic syndrome. METHODS: We did a retrospective, pharmacokinetic-pharmacodynamic analysis of data from patients with acute lymphoid leukaemia, acute myeloid leukaemia, or myelodysplastic syndrome receiving their first T-cell repleted allogeneic peripheral blood stem cell HCT with ATG (thymoglobulin) as part of non-myeloablative conditioning from March 1, 2004, to June 1, 2015. Patients received a cumulative intravenous dose of 8 mg/kg divided over 4 days, starting on day -8 before HCT. Active ATG concentrations were measured using a validated bioassay and pharmacokinetic exposure measures (maximum concentration, concentration at time of infusion of the graft, time to reach a concentration of 1 arbitary unit [AU] per day/mL, area under the curve [AUC], and the AUC before and after HCT) were calculated with a validated population pharmacokinetic model. The main outcome of interest was 5-year overall survival, defined as days to death from any cause or last follow-up. Other outcomes were relapse-related mortality, non-relapse mortality, event-free survival, acute and chronic GvHD, and assessment of current and optimum dosing. We used Cox proportional hazard models and Fine-Gray competing risk models for the analyses. FINDINGS: 146 patients were included. ATG exposure after HCT was shown to be the best predictor for 5-year overall survival. Optimum exposure after transplantation was determined to be 60-95 AU per day/mL. Estimated 5-year overall survival in the group who had optimum exposure (69%, 95% CI 55-86) was significantly higher than in the group who had below optimum exposure (32%, 20-51, p=0·00037; hazard ratio [HR] 2·41, 95% CI 1·15-5·06, p=0·020) and above optimum exposure (48%, 37-62, p=0·030; HR 2·11, 95% CI 1·04-4·27, p=0·038). Patients in the optimum exposure group had a greater chance of event-free survival than those in the below optimum exposure group (HR 2·54, 95% CI 1·29-5·00, p=0·007; HR for the above optimum group: 1·83, 0·97-3·47, p=0·063). Above-optimum exposure led to higher relapse-related mortality compared with optimum exposure (HR 2·66, 95% CI 1·12-6·31; p=0·027). Below optimum exposure increased non-relapse mortality compared with optimum exposure (HR 4·36, 95% CI 1·60-11·88; p=0·0040), grade 3-4 acute GvHD (3·09, 1·12-8·53; p=0·029), but not chronic GvHD (2·38, 0·93-6·08; p=0·070). Modelled dosing based on absolute lymphocyte counts led to higher optimum target attainment than did weight-based dosing. INTERPRETATION: Exposure to ATG affects survival after HCT in adults, stressing the importance of optimum ATG dosing. Individualised dosing of ATG, based on lymphocyte counts rather than bodyweight, might improve survival chances after HCT. FUNDING: Netherlands Organization for Health Research and Development and Queen Wilhelma Fund for Cancer Research.
引用
- Admiraal R, Nierkens S, de Witte MA, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017. PMID: 28330607. doi:10.1016/S2352-3026(17)30029-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。